SCHEMBL4559296

SCHEMBL4559296

COc1cccc(NC(=O)CN2CCNCC2)c1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.60
KMT2A Q03164 7/20 0.55
MEN1 O00255 6/20 0.55
TSHR P16473 3/20 0.53
MAPT P10636 2/20 0.53
LMNA P02545 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
RAB9A P51151 1/20 0.53
NPSR1 Q6W5P4 3/20 0.52
CYP1A2 P05177 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
USP2 O75604 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
HTT P42858 1/20 0.51
POLB P06746 1/20 0.51
CCNE2 O96020 1/20 0.49
CDK4 P11802 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1646834 0.89 ALDH1A1 (0.76) ALDH1A1KMT2AMEN1TSHRMAPT
SCHEMBL11847704 0.85 ALDH1A1 (0.55) ALDH1A1KMT2AMEN1TSHRLMNA
SCHEMBL29832051 0.79 TDP1 (0.76) ALDH1A1KMT2AMEN1MAPTLMNA
SCHEMBL4559520 0.79 L3MBTL1 (0.61) ALDH1A1KMT2AMEN1L3MBTL1RAB9A
SCHEMBL7279555 0.79 ALDH1A1 (0.54) ALDH1A1KMT2AMEN1MAPTNPSR1
SCHEMBL10914678 0.78 ALDH1A1 (0.72) ALDH1A1KMT2AMEN1TSHRLMNA
SCHEMBL1080002 0.77 MEN1 (0.65) ALDH1A1KMT2AMEN1MAPTLMNA
SCHEMBL1644836 0.77 ALDH1A1 (0.97) ALDH1A1KMT2AMEN1TSHRMAPT
SCHEMBL10775964 0.77 SMN1; SMN2 (0.72) ALDH1A1KMT2AMEN1TSHRMAPT
SCHEMBL1646961 0.76 ALDH1A1 (1.00) ALDH1A1KMT2AMEN1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501407-B2 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2009-03-10 US disclosed
US-6916804-B2 Pyrimidine A2b selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2005-07-12 US disclosed
US-20050119271-A1 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119271-A1 Pyrimidine A2B selective antagonist compounds, their synthesis and use ADORA2B, ADORA2A, ADORA3 ALDH1A1 2146/4885KMT2A 2079/4885MEN1 4340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.